These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38193055)

  • 21. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
    Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R
    J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.
    Kumar V; Shaw JR; Key NS; Ilich A; Mallick R; Wells PS; Carrier M
    Oncologist; 2020 Dec; 25(12):1075-1083. PubMed ID: 32969580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study.
    Posch F; Riedl J; Reitter EM; Crowther MJ; Grilz E; Quehenberger P; Jilma B; Pabinger I; Ay C
    J Thromb Haemost; 2020 Jun; 18(6):1348-1356. PubMed ID: 32073229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.
    Mauracher LM; Posch F; Martinod K; Grilz E; Däullary T; Hell L; Brostjan C; Zielinski C; Ay C; Wagner DD; Pabinger I; Thaler J
    J Thromb Haemost; 2018 Mar; 16(3):508-518. PubMed ID: 29325226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
    Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
    J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.
    Shrivastava S; Ridker PM; Glynn RJ; Goldhaber SZ; Moll S; Bounameaux H; Bauer KA; Kessler CM; Cushman M
    J Thromb Haemost; 2006 Jun; 4(6):1208-14. PubMed ID: 16706961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism.
    Han D; ó Hartaigh B; Lee JH; Cho IJ; Shim CY; Chang HJ; Hong GR; Ha JW; Chung N
    PLoS One; 2016; 11(4):e0153514. PubMed ID: 27073982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a D-Dimer Protocol for Detection of Venous Thromboembolism.
    Karsy M; Azab MA; Harper J; Abou-Al-Shaar H; Guan J; Eli I; Brock AA; Ormond RD; Hosokawa PW; Gouripeddi R; Butcher R; Cole CD; Menacho ST; Couldwell WT
    World Neurosurg; 2020 Jan; 133():e774-e783. PubMed ID: 31605841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the risk of venous thromboembolism in multiple myeloma.
    Sanfilippo KM
    Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study.
    van Es N; Louzada M; Carrier M; Tagalakis V; Gross PL; Shivakumar S; Rodger MA; Wells PS
    Thromb Res; 2018 Mar; 163():41-46. PubMed ID: 29353682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
    Luo S; Vasbinder A; Du-Fay-de-Lavallaz JM; Gomez JMD; Suboc T; Anderson E; Tekumulla A; Shadid H; Berlin H; Pan M; Azam TU; Khaleel I; Padalia K; Meloche C; O'Hayer P; Catalan T; Blakely P; Launius C; Amadi KM; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Altintas I; Eugen-Olsen J; Williams KA; Volgman AS; Reiser J; Hayek SS;
    J Am Heart Assoc; 2022 Sep; 11(18):e025198. PubMed ID: 35924778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
    Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
    Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Risk Factors of Multiple Myeloma Complicated with Venous Thromboembolism].
    Zhao BN; Dong CX; Kang JM; Ge XY; Zhang JH; Wang MF; Yang LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1100-1107. PubMed ID: 37551483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.
    Kearon C; Parpia S; Spencer FA; Schulman S; Stevens SM; Shah V; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Connors JM; Ginsberg JS; Spadafora L; Julian JA
    J Thromb Haemost; 2019 Jul; 17(7):1144-1152. PubMed ID: 31033194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-dimer levels over time after anticoagulation and the association with recurrent venous thromboembolism.
    Steinbrecher O; Šinkovec H; Eischer L; Kyrle PA; Eichinger S
    Thromb Res; 2021 Jan; 197():160-164. PubMed ID: 33220565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the predictive value of Padua and the IMPEDE assessment scores for venous thromboembolism in patients with newly diagnosed multiple myeloma: A single institution experience].
    Fang LJ; Yao XD; Lu MQ; Chu B; Shi L; Gao S; Xiang QQ; Wang YT; Liu X; Ding YH; Chen Y; Wang MZ; Zhao X; Hu WK; Sun K; Bao L
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):395-400. PubMed ID: 37550189
    [No Abstract]   [Full Text] [Related]  

  • 39. Venous thromboembolism in multiple myeloma is associated with increased mortality.
    Schoen MW; Carson KR; Luo S; Gage BF; Li A; Afzal A; Sanfilippo KM
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1203-1210. PubMed ID: 33134785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma.
    Sánchez Prieto I; Gutiérrez Jomarrón I; Martínez Vázquez C; Rodríguez Barquero P; Gili Herreros P; García-Suárez J
    J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38676874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.